About DiaSorin
DiaSorin is a publicly listed company based in Saluggia (Italy) founded in 1968. Reagent kits for in vitro diagnostics are developed and commercialized. The company has 30 employees. DiaSorin has completed 2 acquisitions, including Focus DX and Luminex Corporation. Its website diasorin.com draws about 77 thousand monthly visits. Its Indian entity Diasorin Healthcare India Private Limited reported revenue of ₹64.18 Cr. DiaSorin offers products and services including LIAISON XL, VERIGENE System, MAGPIX System, and Simplexa COVID-19 & Flu A/B. Its focus areas include Diversified Diagnostics.
Company details
DiaSorin was founded in 1968 in Saluggia, Italy. Reagent kits for in vitro diagnostics are developed and commercialized, with emphasis on immunodiagnostics and molecular diagnostics sectors. These kits are applied in hospital and private testing laboratories for infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology, and endocrinology. Offices are operated in Europe, the United States, Central and South America, Asia, and South Africa as of January 2016.
- Headquarters Saluggia, Italy
- Employees 30
- Stage Public
- SectorsHealthcare
- Website int.diasorin.com/en
- Social LinkedIn X Facebook
- Legal Name Diasorin S.P.A.
Associated legal entities of DiaSorin
DiaSorin operates through Diasorin Healthcare India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Diasorin Healthcare India Private Limited CIN U85100MH2012FTC323879 | Active | 10 Jul 2012 | Mumbai, Maharashtra | ₹64.2 Cr | 30 | 5 | View details |
Products & Services of DiaSorin
DiaSorin offers a comprehensive portfolio of products and services, including LIAISON XL, VERIGENE System, MAGPIX System, and Simplexa COVID-19 & Flu A/B.
Instrument for immunodiagnostic testing of infectious diseases
System for detecting pathogens in biological samples
Platform for bead-based multiplexing in diagnostics
Kit for identifying respiratory viruses quickly
Funding Insights of DiaSorin
- Total Rounds 5
- First Round $1.12M
(Mar 2009)
- Investors Count 2
All 5 funding rounds of DiaSorin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | Grant | – | – | ||
| Dec 2020 | Grant | – | – | ||
| Nov 2020 | $820,000 | Grant | – | – | |
| Jun 2009 | $173,066 | Grant | – | – | |
| Mar 2009 | $1.12M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in DiaSorin
DiaSorin has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Public Health Emergency.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| phe.gov | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for DiaSorin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Diasorin Healthcare India Private Limited (DiaSorin)
Diasorin Healthcare India Private Limited is the primary company behind DiaSorin. The board of Diasorin Healthcare India Private Limited currently have 4 directors; the longest-serving is John Alexander Hoffarth, appointed in 2020. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| John Alexander Hoffarth DIN 08734737 | Director | 29 Jun 2020 | 6 yrs 3 mo | Diasorin Healthcare India Private Limited |
| Joshua Glason DIN 10052715 | Director | 02 Mar 2023 | 3 yrs 7 mo | Diasorin Healthcare India Private Limited |
| Valerio Vaccarone DIN 10052786 | Additional Director | 02 Mar 2023 | 3 yrs 7 mo | Diasorin Healthcare India Private Limited |
| Prem Kumar Charles DIN 10639781 | Managing Director | 29 May 2024 | 2 yrs 4 mo | Diasorin Healthcare India Private Limited |
People of DiaSorin
95 people are tracked at DiaSorin (49 in leadership, 1 in board & advisors, 45 in team); the tracked headcount is 30.
| Name | Role | Group |
|---|---|---|
Kristie Brok | HR Director Benelux, France, Iberia & LTG EMEA | Leadership |
Josh Glason | Vice President Asia Pacific | Leadership |
Jesse Nergard | Director Of Talent Acquisition, North America | Leadership |
Doug Whitman | Senior Director, Advanced Technology Group At Luminex Corporation, A Diasorin Company | Leadership |
Chen Even | Chief Commercial Officer | Leadership |
Dave Blomberg | Vice President, Sales - Molecular | Leadership |
Amelia Parente | Senior Vice President Corporate HR | Leadership |
Carlo Rosa | CEO | Leadership |
Ralph Michielli | Regional Sales Director | Leadership |
Kristy Hanson | Vice President Of Strategic Accounts | Leadership |
Fabrizio Momblano | Corporate Treasury Director | Leadership |
Leslie Vasquez | Senior Talent Acquisition Partner | Leadership |
Angelo Rago | President, Luminex Corporation | Leadership |
Liana Ryder | Vice President Immuno | Leadership |
Nineveh Sarggis | Senior Director US Commercial Labs East | Leadership |
Fernando Davico | Corporate Vice President Sales Emea, APAC & Latam | Leadership |
Alessandro Pellarin | Corporate VP Commercial Excellence | Leadership |
Joel Cowen | Vice President, Commercial - Immuno | Leadership |
Matteo Pinciroli | Corporate Vice President Market Access | Leadership |
Luca de Rosa | Corporate Director Commercial Business Development | Leadership |
75 more people are available in the full profile.
Complete people profiles for DiaSorin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of DiaSorin
DiaSorin is a publicly listed company on the MIL with ticker symbol DIA in Italy, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Jul 2007
- Listed onMIL: DIA
- Listed entityDiaSorin S.p.A.
- Exchange sectorHealth technology
- ISINIT0003492391
- Share price78.38 EUR (+0.28% on the day) · 2026-10-14
- Market capitalisation4,216,208,098.00 EUR
- Price to earnings29.7
- EPS (diluted, trailing year)2.64 EUR
- Dividend yield1.66%
- Volume (last session)9,337
Financials of DiaSorin
Figures of Diasorin Healthcare India Private Limited, the primary company behind DiaSorin, for FY 2025. Revenue was ₹64.18 Cr (+14% year on year). Net profit was ₹7.88 Cr (12% margin). EBITDA was ₹7.90 Cr (12% margin). Revenue has grown at a compounded annual rate of +6% over three years and +15% over five years.
- ₹64.18 CrRevenue · FY 2025 · +14% YoY
- ₹7.88 CrNet profit · 12% margin
- ₹7.90 CrEBITDA · 12% margin
- ₹47.00 CrPaid-up capital
- 30Employees (provident fund records)
- +6%Revenue CAGR, 3 years
- +15%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.20B EUR | 155.6M EUR | 432.8M EUR |
| 2024 | 1.19B EUR | 188.1M EUR | 406.7M EUR |
| 2023 | 1.15B EUR | 159.8M EUR | 350.8M EUR |
| 2022 | 1.36B EUR | 240.9M EUR | 501.6M EUR |
| 2021 | 1.24B EUR | 311.0M EUR | 527.9M EUR |
Balance sheet, profit and loss, cash flow and ratios of Diasorin Healthcare India Private Limited are on its company page.
Detailed financial statements for DiaSorin
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DiaSorin
DiaSorin has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Focus DX and Luminex Corporation.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of instruments, reagents and kits for clinical diagnostics and life science research | luminexcorp.com | Austin, United States | 1995 | Apr 2021 | $1.8B | |
Diagnostic assays and reagents for infectious diseases are developed. | focusdx.com | Cypress, United States | 1978 | Mar 2016 | $300M |
Complete acquisition details for DiaSorin
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of DiaSorin
6 dated milestones of DiaSorin across 53 years, from founding to its latest funding, stage changes and deals.
- Founded DiaSorin is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.1M.
- Acquisition Acquires Focus DX.
- Funding Latest funding round, Grant,.
- Acquisition Acquires Luminex Corporation.
Web traffic of DiaSorin
The website of DiaSorin (diasorin.com) receives about 76.8K visits a month.
- Monthly visits76.8K
▲ 16.3% vs previous month
Websites whose visitors overlap most with DiaSorin. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sorin.com | 100% | View details | |||
| questdiagnostics.com | 96% | 14.4M | #2,905 | View details | |
monobind.com | monobind.com | 79% | #1,065,552 | – | |
| instrumentationlaboratory.com | 78% | View details | |||
| quidel.com | 76% | #5,902,749 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for DiaSorin
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Diasorin
Complete news archive for DiaSorin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DiaSorin
DiaSorin was founded in 1968 and raised its 1st funding round 41 years after it was founded.
DiaSorin is headquartered in Saluggia, Italy. It is registered at Saluggia, Piemonte, Italy.
DiaSorin has 30 employees.
The primary company behind DiaSorin, Diasorin Healthcare India Private Limited, reported revenue of ₹64.18 Cr for FY 2025, up 14% year on year.
DiaSorin was founded in 1968 in Saluggia, Italy. Reagent kits for in vitro diagnostics are developed and commercialized, with emphasis on immunodiagnostics and molecular diagnostics sectors. These kits are applied in hospital and private testing laboratories for infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology, and endocrinology. Offices are operated in Europe, the United States, Central and South America, Asia, and South Africa as of January 2016.
DiaSorin offers LIAISON XL, VERIGENE System, MAGPIX System, and Simplexa COVID-19 & Flu A/B.
Yes, DiaSorin is publicly traded on MIL under the ticker symbol DIA.
DiaSorin has made 2 acquisitions, including Focus DX, and Luminex Corporation.
DiaSorin has 2 investors. Key investors include HHS, and Public Health Emergency.
DiaSorin operates through Diasorin Healthcare India Private Limited.
The legal entities of DiaSorin currently have 5 directors, including John Alexander Hoffarth, Prem Kumar Charles, Joshua Glason and others.